Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Target-Kategorie:
CLDN18.2
ELISA plates were pre-coated with 0.5ug/per well purified human CLDN18.2 VLP. Serial diluted Anti-CLDN18.2 monoclonal antibody (Zolbetuximab biosililar, IMAB362) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for IMAB362 binding with CLDN18.2 VLP is 15.37 ng/ml.
FACS analysis of CLDN18.2 VLP.A. Negative Control 1: CLDN18.2 VLP were stained only with Goat anti-human IgG Fc-PE secondary antibody.B. Negative Control 2: Control VLP were stained with anti-CLDN18.2 antibody (Zolbetuximab biosimilar, IMAB362) at 1 µg/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.C. Negative Control 3: CLDN18.2 VLP were stained with anti-BCMA antibody (an irrelevant antibody) at 1 µg/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.D. CLDN18.2 VLP were stained with anti-CLDN18.2 antibody (Zolbetuximab biosimilar, IMAB362) at 1 µg/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
